GSC
KZR

Ground Swell Capital’s Kezar Life Sciences KZR Stock Holding History

Ground Swell Capital’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,080
Closed -$8.35K – 210
2024
Q3 		$8.35K Buy
+1,080
New +$6.51K 0.01% 146

Other funds holding KZR

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Ground Swell Capital's KZR Position: Q4 2024 in Review

Ground Swell Capital sold out of Kezar Life Sciences (KZR) in Q4 2024, closing a stake of 1,080 shares — an estimated $8.35K sold.

Ground Swell Capital first reported a position in KZR in Q3 2024 and held it in 1 quarter. The position peaked at $8.35K in Q3 2024. 43 funds tracked by Wall St. Rank hold KZR as of Q4 2024.

  • Ground Swell Capital reported no remaining Kezar Life Sciences position as of Q4 2024 after selling out during the quarter.
  • Ground Swell Capital sold 1,080 Kezar Life Sciences shares in Q4 2024, an estimated $8.35K.
  • Ground Swell Capital first reported a position in Kezar Life Sciences in Q3 2024 and held it in 1 quarter.
  • Ground Swell Capital's Kezar Life Sciences position peaked at $8.35K in Q3 2024.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2024.

Based on Ground Swell Capital's 13F filing for Q4 2024, filed 14 Feb 2025.